drsairahahmed

"Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma" Keywords: #Parkinsonism, CAR T-cell therapy, Cilta-cel, Multiple #myeloma, #Ruxolitinib jh.elmerpub.com/jh/article/vie…

HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Whether you're early on in your career or experienced in the field of #Lymphoma, staying current matters. Join the #LymphomaManagement course for four weekly sessions of expert teaching - live or recorded. Book today 👉 lymphoma-action.org.uk/events/lymphom… #LymSM @tobyeyre82 @graham74GC

A @CIBMTR study examines CRS & ICANS in LBCL patients treated with CAR T therapies. Highlights: ICANS rates remain stable; CRS & ICANS are strongly correlated; Severe forms of these toxicities are associated with reduced overall survival. Read here: tinyurl.com/4tnurfas

🔥 Lymphoma updates from the summer congresses. In this rapid fire conversation with @chadinabhan, I explore the highest yield data: what’s ready for prime time and hot topics to lookout for. Do give a listen 🙏🏻. @MSKCancerCenter @MSK_DeptOfMed @HemOncFellows @OncBrothers

Don't miss this week's WILing wednesday! Dr Thieblemont and Dr Arai answering one of the questions frequently asked in the clinic: do infectious agents drive lymphoma initiation? Link below

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH

Cytopenias and infections following SOC cilta-cel in RRMM. N=105, Day 30 ICAHT: 10%, at > day 30: 3.3%. ~10% required stem cell boost. Infections in 49% #mmsm #bmtsm @DimaDanai @SurbhiSidanaMD @DrKrinaPatel haematologica.org/article/view/1…

Just published in @ASCOPost My reflections from ICML 2025 — where lymphoma history met its future. From COO giving way to molecular clusters, to the TME guiding CART outcomes, to the undeniable momentum in aggressive B-cell lymphoma 👉 ascopost.com/news/july-2025… #ICML2025 #lymsm

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial - The Lancet Oncology thelancet.com/journals/lanon…

Congrats Dr Hassan Kaleem on an informative heme/onc CME at @APPNA annual meeting with @SyedKazmiMD @awandoc and Dr Sultan Chowdhary @humeraaqamar

The Foundation's Lymphoma Scientific Research Mentoring Program gave Dr. Priyanka Pophali's (@uwcarbone) the support needed to kickstart her work focused on improving outcomes and quality of life for lymphoma survivors. Read more in the latest Pulse: lymphoma.org/news/where-are…

1/ Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from? A short 🧵 on the origins, function, and significance of Ki-67.…

Fresh from #ICML2025 💜 Prof Jessica Okosun outlines key #FollicularLymphoma findings: - Tafasitamab + R2 gets FDA approval - ELARA confirms CAR T long-term impact - Bispecific antibodies advance globally Full report on our scientific learnings coming soon!

Our next series of webinars starts next week - register to join live for a presentation by Marie Donzel, @jenamengual, hosted by Florence Broussais, @SoniSmithMD and Amira Marouf Pathogens and Lymphoma - EBV and lymphomagenesis us06web.zoom.us/webinar/regist…

Problem: these classification tools are not accessible to vast majority of oncologists (particularly in the community where majority of DLBCL is treated). Very challenging to say from the podium that we should be doing this in routine clinical practice. #lymsm #18ICML 1/

Baseline A-HIPI is prognostic across HL disease course and high risk patients are at higher risk of adverse outcomes than lower risk even after achieving an iPET negative scan or achieving CR after EOT. #ASH24 #lymsm #HL

Lonca + glofi in R/R LBCL @JuanAlderuccio #18ICML - 41 pts, 55% IPI 3+, 20% prior CAR - no G5 TEAEs, 6 dc'd d/t AEs - 1 G3 CRS, no G3+ ICANS - ORR 93%, DOR NR (25/26 CRs remained in CR) Looking forward to longer f/u. #lymsm

🧵 Game-changer for older #HodgkinLymphoma patients (≥60 yrs)! In the SWOG S1826 trial, Nivolumab-AVD outperformed Brentuximab-AVD in advanced-stage cHL: 🔹 2-yr PFS: 89% vs 64% 🔹 2-yr OS: 96% vs 85% 🔹 Better tolerance, less non-relapse mortality (6% vs 16%) ✅ N-AVD is now…

The new debate in advanced stage HL treatment. #18ICML #ICML2025